Merck: targets upped for 2023
(CercleFinance.com) - On the occasion of its first-quarter results, Merck indicates that it has raised its target adjusted EPS range for the full-year 2023 to between 6.
88 and 7 dollars, as well as that of its global sales, to between 57.7 and 58.9 billion dollars.
Over the first three months of the year, the healthcare group has seen its adjusted EPS shrink 35% to 1.40 dollars, for a fall in revenue of 9% to 14.5 billion, but outside Lagevrio and exchange rate effects, it reports a 15% growth.
“First quarter 2023 reflected continued strong underlying performance across key growth drivers, particularly in oncology and vaccines”, underlines Merck, also highlighting a 20% increase in sales for Keytruda and 35% for Gardasil.
Copyright (c) 2023 CercleFinance.com. All rights reserved.